Isabel Kalofonos - 10 Jan 2025 Form 4 Insider Report for Crinetics Pharmaceuticals, Inc. (CRNX)

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CRNX	Stock Option (Right to Buy)	Award	$0	+100,000		$0.000000	100,000	10 Jan 2025	Common Stock	100,000	$40.59	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Id	Content
F1	The option is exercisable as follows: 25% of the shares subject to the option vest on December 16, 2025, and the remaining number of shares subject to the option vest monthly thereafter in thirty-six equal monthly installments, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.